|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 191.50 °C. @ 760.00 mm Hg
|
| Boiling Point: | 336.90 °C. @ 760.00 mm Hg (est)
|
| Vapor Pressure: | 0.000056 mmHg @ 25.00 °C. (est) |
| Flash Point: | 316.00 °F. TCC ( 157.50 °C. ) (est)
|
| logP (o/w): | 1.816 (est) |
| Soluble in: |
| | water, 2709 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-hamster LD50 166 mg/kg BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ATAXIA Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 75, 1960.
oral-hamster LD50 662 mg/kg BEHAVIORAL: ATAXIA
BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 75, 1960.
intraperitoneal-mammal (species unspecified) LD50 550 mg/kg BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) Chimica Therapeutica. Vol. 6, Pg. 65, 1971.
oral-man TDLo 50 mg/kg BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: COMA American Journal of Emergency Medicine. Vol. 16, Pg. 393, 1998.
intraperitoneal-mouse LD50 50 mg/kg National Technical Information Service. Vol. AD277-689
oral-mouse LD50 440 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 242, 1967.
intraperitoneal-rat LD50 150 mg/kg BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: ATAXIA Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 75, 1960.
oral-rat LD50 763 mg/kg BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: ATAXIA Journal of Pharmacology and Experimental Therapeutics. Vol. 129, Pg. 75, 1960.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 170 mg/kg BEHAVIORAL: ANTICONVULSANT Acta Pharmacologica et Toxicologica. Vol. 19, Pg. 247, 1962.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for chlorzoxazone usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for chlorzoxazone flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 2- | benzoxazolinone, 5-chloro- | | 2- | benzoxazolol, 5-chloro- | | 2(3H)- | benzoxazolone, 5-chloro- | | 5- | chlorbenzoxazolin-2-one | | 5- | chloro-1,3-benzoxazol-2(3H)-one | | 5- | chloro-2-benzoxazolinone | | 5- | chloro-2-hydroxybenzoxazole | | 5- | chloro-2,3-dihydro-2-oxo-1,3-benzoxazole | | 5- | chloro-2(3H)-benzoxazolone | | 5- | chloro-3-hydrobenzoxazol-2-one | | 5- | chloro-3(H)-2-benzoxazolone | | 5- | chloro-3H-1,3-benzoxazol-2-one | | 5- | chloro-3H-benzooxazol-2-one | | 5- | chloro-3H-benzoxazol-2-one | | 5- | chloro-benzooxazol-2-ol | | 5- | chlorobenzoxazol-2-one | | 5- | chlorobenzoxazolidone | | 5- | chlorobenzoxazolin-2-one | | | chloroxazone | | | chlorsoxazone | | | chlorzoxane | | | chlorzoxazon | | 2- | hydroxy-5-chlorobenzoxazole | | | myoflexin | | | myoflexine | | | neoflex | | | paraflex | | | parafon | | | pathorysin | | | relaxazone | | | solaxin |
Articles:
|